Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000078018 | SCV000109856 | uncertain significance | not provided | 2017-10-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001342759 | SCV001536706 | uncertain significance | Argininosuccinate lyase deficiency | 2021-09-02 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine with lysine at codon 326 of the ASL protein (p.Gln326Lys). The glutamine residue is highly conserved and there is a small physicochemical difference between glutamine and lysine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with ASL-related conditions. ClinVar contains an entry for this variant (Variation ID: 92367). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C45"). This variant disrupts the p.Gln326 amino acid residue in ASL. Other variant(s) that disrupt this residue have been observed in individuals with ASL-related conditions (PMID: 24166829), which suggests that this may be a clinically significant amino acid residue. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV001342759 | SCV003825105 | uncertain significance | Argininosuccinate lyase deficiency | 2022-04-22 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004586540 | SCV005075948 | uncertain significance | not specified | 2024-04-01 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001342759 | SCV002076035 | uncertain significance | Argininosuccinate lyase deficiency | 2021-01-06 | no assertion criteria provided | clinical testing |